• The EGFR kinase inhibitor Erlotinib increased Bim expression in lung cancer cells sensitive to the drug, but not in resistant cells.• Bcl-2 inhibits the cell death induced by erlotinib. Here, BCL2L11 is linked to lung carcinoma.